fidaxomicin 和其主要代谢产物 OP-1118 对艰难梭菌的抗生素后效应。
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
机构信息
Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Rd., Suite C, San Diego, CA 92121, USA.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
Abstract
Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).
摘要
非达霉素（FDX）是一种窄谱抗生素，最近的研究表明，它在治疗艰难梭菌感染方面优于万古霉素，能提供持续的临床应答。本研究检测了 FDX 及其主要代谢产物 OP-1118 的抗生素后效应（PAE）。结果显示，FDX 的 PAE 较长（ATCC 株为 10 h，临床分离株为 5.5 h），而 OP-1118 的 PAE 长于标准对照药万古霉素（分别为 3 h 和 0-1.5 h）。
相似文献
1
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. fidaxomicin 和其主要代谢产物 OP-1118 对艰难梭菌的抗生素后效应。
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
2
Fidaxomicin inhibits spore production in Clostridium difficile.非达霉素抑制艰难梭菌的孢子生成。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S162-9. doi: 10.1093/cid/cis453.
3
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.非达霉素和万古霉素均可抑制艰难梭菌孢子的生长。
Antimicrob Agents Chemother. 2013 Jan;57(1):664-7. doi: 10.1128/AAC.01611-12. Epub 2012 Nov 12.
4
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.法昔洛韦及其主要代谢物 OP-1118 对艰难梭菌的杀菌动力学。
J Med Microbiol. 2011 Aug;60(Pt 8):1213-1217. doi: 10.1099/jmm.0.029470-0. Epub 2011 Feb 24.
5
Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.艰难梭菌中转录抑制剂非达霉素与利福霉素的比较微生物学研究
Antimicrob Agents Chemother. 2014 May;58(5):2934-7. doi: 10.1128/AAC.02572-13. Epub 2014 Feb 18.
6
Antimicrobial activities of fidaxomicin. fidaxomicin 的抗菌活性。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S143-8. doi: 10.1093/cid/cis339.
7
Fidaxomicin: in Clostridium difficile infection.非达霉素：治疗艰难梭菌感染。
Drugs. 2011 Dec 24;71(18):2445-56. doi: 10.2165/11208220-000000000-00000.
8
Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.接种物、pH 值和阳离子对 fidaxomicin（OPT-80，PAR-101）体外抗艰难梭菌活性的影响。
Antimicrob Agents Chemother. 2010 Jun;54(6):2674-6. doi: 10.1128/AAC.01842-09. Epub 2010 Mar 22.
9
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.艰难梭菌生物膜分析：成像与抗菌治疗。
J Antimicrob Chemother. 2018 Jan 1;73(1):102-108. doi: 10.1093/jac/dkx353.
10
and Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.新型喹诺酮化合物OPS-2071对艰难梭菌的抗菌活性
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01170-20.
引用本文的文献
1
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.复发性艰难梭菌感染：当前的临床管理及基于微生物群的治疗方法
BioDrugs. 2023 Nov;37(6):757-773. doi: 10.1007/s40259-023-00617-2. Epub 2023 Jul 26.
2
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.成人艰难梭菌感染的管理及临床实践中的挑战：对当前 IDSA/SHEA、ESCMID 和 ASID 指南的回顾与比较。
J Antimicrob Chemother. 2022 Dec 23;78(1):21-30. doi: 10.1093/jac/dkac404.
3
Fidaxomicin for the Treatment of Infection in Adult Patients: An Update on Results from Randomized Controlled Trials.非达霉素用于治疗成年患者感染：随机对照试验结果的最新进展
Antibiotics (Basel). 2022 Oct 6;11(10):1365. doi: 10.3390/antibiotics11101365.
4
Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.美国一家医院系统实施非达霉素治疗优化与获取途径后的临床和经济结果
Infect Dis Ther. 2023 Jan;12(1):95-107. doi: 10.1007/s40121-022-00665-1. Epub 2022 Jul 19.
5
Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection.非达霉素作为暴发性艰难梭菌感染的挽救疗法
Cureus. 2021 Jul 22;13(7):e16559. doi: 10.7759/cureus.16559. eCollection 2021 Jul.
6
Fidaxomicin for the treatment of in children. fidaxomicin 治疗儿童。
Future Microbiol. 2020 Jul;15(11):967-979. doi: 10.2217/fmb-2020-0104. Epub 2020 Jul 27.
7
Scientific validation of the antimicrobial and antiproliferative potential of Berberis aristata DC root bark, its phytoconstituents and their biosafety.小檗根皮、其植物成分的抗菌和抗增殖潜力及其生物安全性的科学验证。
AMB Express. 2019 Sep 11;9(1):143. doi: 10.1186/s13568-019-0868-4.
8
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.非达霉素与万古霉素治疗艰难梭菌感染初发 episode：一项荟萃分析与系统评价
Cureus. 2018 Jun 11;10(6):e2778. doi: 10.7759/cureus.2778.
9
Management of Primary and Recurrent Infection: An Update.原发性和复发性感染的管理：最新进展
Antibiotics (Basel). 2018 Jun 30;7(3):54. doi: 10.3390/antibiotics7030054.
10
Antibiotic Treatments for Infection Are Associated with Distinct Bacterial and Fungal Community Structures.感染的抗生素治疗与独特的细菌和真菌群落结构相关。
mSphere. 2018 Jan 10;3(1). doi: 10.1128/mSphere.00572-17. eCollection 2018 Jan-Feb.
本文引用的文献
1
Fidaxomicin versus vancomycin for Clostridium difficile infection. fidaxomicin 与万古霉素治疗艰难梭菌感染。
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
2
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.一种新型大环抗生素，非达霉素（OPT-80），相较于万古霉素，引起艰难梭菌感染患者肠道微生物群改变更小。
Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. doi: 10.1099/mic.0.042010-0. Epub 2010 Aug 19.
3
Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. fidaxomicin (OPT-80) 治疗艰难梭菌感染。
Expert Opin Pharmacother. 2010 Jun;11(9):1569-78. doi: 10.1517/14656566.2010.485614.
4
Clostridium difficile infection: new developments in epidemiology and pathogenesis.艰难梭菌感染：流行病学与发病机制的新进展
Nat Rev Microbiol. 2009 Jul;7(7):526-36. doi: 10.1038/nrmicro2164.
5
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.OPT-80可清除艰难梭菌，且在治疗艰难梭菌感染期间对拟杆菌属菌种无损害。
Antimicrob Agents Chemother. 2009 Jan;53(1):261-3. doi: 10.1128/AAC.01443-07. Epub 2008 Oct 27.
6
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.OPT-80 针对产毒素艰难梭菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2008 Nov;52(11):4163-5. doi: 10.1128/AAC.00476-08. Epub 2008 Aug 25.
7
Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.单次和多次口服给药后OPT-80在健康志愿者中的安全性、耐受性和药代动力学研究。
Antimicrob Agents Chemother. 2008 Apr;52(4):1391-5. doi: 10.1128/AAC.01045-07. Epub 2008 Feb 11.
8
Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.万古霉素、甲硝唑和夫西地酸对艰难梭菌的药效学研究。
Chemotherapy. 2007;53(4):267-74. doi: 10.1159/000104471. Epub 2007 Jun 25.
9
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.1983年至2004年收集的110株产毒素艰难梭菌临床分离株对15种抗菌药物的体外活性
Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9. doi: 10.1128/AAC.01623-06. Epub 2007 May 21.
10
Alternative treatments for Clostridium difficile disease: what really works?艰难梭菌疾病的替代治疗方法：究竟哪些有效？
J Med Microbiol. 2005 Feb;54(Pt 2):101-111. doi: 10.1099/jmm.0.45753-0.
Zotero 插件